Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01563874 · ClinicalTrials.gov registry record

Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins

A clinical trial, sponsored by National Cancer Institute (NCI).

Completed
Registry status
130
Enrollment target

NCT01563874: Completed study, sponsored by National Cancer Institute (NCI).

NCT01563874 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 130 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01563874 has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
130 participants
Enrollment target

Study Summary

BACKGROUND: Lymphomas are comprised of a diversity of tumors with different pathologic and clinical features. While distinct differences in gene expression profiles have been elucidated in different lymphomas, there has been inconsistent correlation with the few published proteomic studies. Greater insights into the biology of lymphomas may be achieved by integrating current genomic information with additional studies focused on the interrelationships in tumors of the patterns of chromatin protein expression, chromatin protein modification, and RNA expression profiling (both within bulk tumor and within specific microscopic tumor niches accessible by microdissection and cell sorting approaches). OBJECTIVES: The goals of this protocol are to identify the global levels of all histones (including variant histones) and non-histone chromosomal proteins, and to measure the relative levels of most known covalent modifications on histone and non-histone chromosomal proteins. For a limited number of cases illustrative of selected pathological entities, we propose to map the genome-wide distribution of those modifications judged to be biochemically instructive. ELIGIBILITY: This work will involve the analysis of a broad panel of lymphoma and lymphoid samples, which were previously procured under multiple protocols at the NIH, and for which there is excess tissue available for research. We also request permission to extend this analysis to surplus materials to be accrued under existing protocols, upon completion of all superseding diagnostic tests and medical/scientific studies. The criteria for inclusion in this study are subsumed under the enveloping protocols. The number of cases to be included is dependent upon the size of these protocols; because statistical significance improves with increasing numbers. We hope to include up to 300 cases. DESIGN: Lysates from surplus samples will be prepared and arrayed onto microarrays. These arrays will be probed with panels

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2009-06-02

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT01563874

The ClinicalTrials.gov registry entry for NCT01563874 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT01563874 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01563874 about?

NCT01563874 is a clinical study titled "Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins". BACKGROUND: Lymphomas are comprised of a diversity of tumors with different pathologic and clinical features. While distinct differences in gene expression profiles have been elucidated in different lymphomas, there has been inconsistent correlation with the few published proteomic studies. Greate...

What is the current status of trial NCT01563874?

This trial is currently completed. The enrollment target is 130 participants. The study started on 2009-06-02.

Who is sponsoring clinical trial NCT01563874?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.